de Castro M L, Hermo J A, Baz A, de Luaces C, Pérez R, Clofent J
Servicio de Aparato Digestivo, Hospital Meixoeiro-CHUVI Vigo, Pontevedra, Spain.
Gastroenterol Hepatol. 2006 Jan;29(1):21-4. doi: 10.1157/13083248.
Consumption of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA) inhibitors, known as statins, has been associated with elevated transaminase levels but rarely with acute hepatitis. Recently, several cases of acute hepatitis secondary to atorvastatin therapy have been published. We report the case of a 72-year-old man who developed acute cholestatic hepatitis after reinitiating treatment with atorvastatin at a higher dose than that previously prescribed. After treatment discontinuation, the patient made a full recovery, with normalization of clinical and laboratory findings.
服用3-羟基-3-甲基戊二酰辅酶A还原酶(HMG-CoA)抑制剂(即他汀类药物)与转氨酶水平升高有关,但很少引发急性肝炎。最近,已有几例继发于阿托伐他汀治疗的急性肝炎病例发表。我们报告了一例72岁男性患者的病例,该患者在重新开始服用比之前处方剂量更高的阿托伐他汀后出现了急性胆汁淤积性肝炎。停药后,患者完全康复,临床和实验室检查结果恢复正常。